Generate Biomedicines, Inc. (GENB)
| Market Cap | 1.68B |
| Revenue (ttm) | 26.48M +55.9% |
| Net Income | -268.67M |
| EPS | -3.28 |
| Shares Out | 128.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 974,901 |
| Open | 12.53 |
| Previous Close | 12.52 |
| Day's Range | 12.43 - 13.16 |
| 52-Week Range | 11.00 - 22.67 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.00 (+106.74%) |
| Est. Earnings | Nov 3, 2026 |
About GENB
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GENB stock is "Strong Buy." The 12-month stock price target is $27.0, which is an increase of 106.74% from the latest price.
News
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Generate Biomedicines (GENB) announced a multi-target strategic collaboration with Zealand Pharma (ZLDPF). Under the collaboration, the companies intend to design and develop multispecific protein the...
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration...
Generate Biomedicines, Roswell Park dose first patient in GB-5267 trial
Roswell Park Comprehensive Cancer Center and Generate Biomedicines (GENB) announced that the first patient has been dosed in a first-in-human clinical trial evaluating GB-5267. GB-5267 targets the ant...
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical tria...
Generate Biomedicines Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Generative AI and rapid experimental feedback have transformed protein drug design, enabling faster, more precise development and the pursuit of previously undruggable targets. Key assets are advancing quickly, with strategic partnerships and data-driven differentiation shaping future industry models.
Generate Biomedicines Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The platform leverages AI and experimental validation to advance novel protein therapeutics, with a lead TSLP asset in phase III for asthma and COPD, and an innovative oncology program in phase I. Key catalysts include trial enrollments, proof of concept data, and new partnerships.
Generate Biomedicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China’s biotech innovation is intensifying competition, prompting a focus on advanced AI-driven R&D. The platform is validated by GB-0895’s rapid progress and convenience-focused design, with pivotal asthma trials on track and COPD seen as a major opportunity. Strong partnerships and a robust cash position support ongoing development and expansion into oncology and complex biological targets.
Generate Biomedicines Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Founded in 2018, the company leverages machine learning and proprietary data to design protein therapeutics, with a lead long-acting TSLP antibody in phase III for asthma and COPD. The pipeline includes an MMAE neutralizer and a CAR T program for solid tumors, both in early clinical stages. A strong first-mover advantage and robust digital infrastructure support rapid innovation.
Generate Biomedicines Inc. to Participate in September Investor Conferences
SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at th...
Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Generate Biomedicines (GENB) to $30 from $25 and keeps a Buy rating on the shares. The GB-0895 data uphold six-month dosing, the…
Generate Biomedicines falls -16.7%
Generate Biomedicines (GENB) is down -16.7%, or -$3.41 to $16.97.
Generate Biomedicines falls -11.0%
Generate Biomedicines (GENB) is down -11.0%, or -$2.25 to $18.13.
Generate Biomedicines rises 17.7%
Generate Biomedicines (GENB) is up 17.7%, or $3.14 to $20.86.
Generate Biomedicines reports Q2 EPS (52c), consensus (49c)
Reports Q2 revenue $6.31M, consensus $5.3M. “Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicine...
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be p...
Generate Biomedicines Quarterly report: Q2 2026
Generate Biomedicines has published its Q2 2026 quarterly earnings report on August 6, 2026.
Generate Biomedicines Earnings release: Q2 2026
Generate Biomedicines released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Generate Biomedicines falls -9.5%
Generate Biomedicines (GENB) is down -9.5%, or -$1.50 to $14.22.
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced tha...
Generate Biomedicines Slides: Corporate presentation
Generate Biomedicines has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Generate Biomedicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The platform integrates advanced computational and experimental methods to accelerate novel protein drug discovery, with a lead anti-TSLP antibody in phase III for severe asthma and a robust oncology pipeline. Strategic partnerships and a focus on biannual dosing aim to improve compliance and market impact.
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, J...
Generate Biomedicines price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Generate Biomedicines (GENB) to $22 from $20 and keeps an Overweight rating on the shares.
Generate Biomedicines price target raised to $25 from $16 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Generate Biomedicines (GENB) to $25 from $16 and keeps a Buy rating on the shares. The company’s GB-0895 is…